OncoSil Medical Ltd (AU:OSL)
ASX:OSL
OSL Stock Chart & Stats
AU$0.97
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.97
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.46 - AU$2.08
Previous CloseN/A
Volume350.23K
Average Volume (3M)24.03K
Market Cap
AU$15.50M
Enterprise ValueAU$6.77M
Total Cash (Recent Filing)AU$2.85M
Total Debt (Recent Filing)AU$42.47K
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding30,697,231
10 Day Avg. Volume8,764
30 Day Avg. Volume24,029
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.23
Price to Sales (P/S)11.20
P/FCF Ratio-1.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche Product And Clinical FocusOncoSil's device targets locally advanced pancreatic cancer with EUS-guided brachytherapy as an adjunct to chemotherapy. That focused clinical niche addresses a high unmet need, supporting durable physician adoption, clear go-to-market positioning and long-term demand if clinical outcomes remain favorable.
Material Revenue GrowthReported ~31.85% revenue growth indicates the company is gaining commercial traction for its core product. Sustained top-line growth over multiple quarters would support scale benefits, improve operating leverage potential and provide runway for further clinical development or market expansion.
Very Low Financial LeverageA debt-to-equity ratio of ~0.0225 shows minimal leverage, giving the company balance-sheet flexibility. Low interest burden reduces insolvency risk and allows management to pursue clinical programs or partnerships without near-term debt servicing pressure, a structural advantage during commercialization.
Bears Say
Persistent UnprofitabilityDeeply negative gross, net, EBIT and EBITDA margins demonstrate the business currently does not generate operational profits. Persistent unprofitability will erode equity, limit reinvestment capacity and require sustained improvements in pricing, cost structure, or scale to achieve durable viability.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flows signal structural cash burn from operations. This necessitates external financing or asset dilution to fund R&D and commercialization, increasing financing risk and potentially constraining long-term investment in market expansion or clinical programs.
Concentrated Product Exposure And Small TeamReliance on a single core device and a very small employee base concentrates execution, regulatory and commercial risk. Any clinical setback, reimbursement denial or manufacturing issue could materially affect revenues; scaling commercialization may require substantial hires and capital, pressuring resources.
OncoSil Medical Ltd News
OSL FAQ
What was OncoSil Medical Ltd’s price range in the past 12 months?
OncoSil Medical Ltd lowest share price was AU$0.46 and its highest was AU$2.08 in the past 12 months.
What is OncoSil Medical Ltd’s market cap?
OncoSil Medical Ltd’s market cap is AU$15.50M.
When is OncoSil Medical Ltd’s upcoming earnings report date?
OncoSil Medical Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 139 days.
How were OncoSil Medical Ltd’s earnings last quarter?
OncoSil Medical Ltd released its earnings results on Feb 23, 2026. The company reported -AU$0.242 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.242.
Is OncoSil Medical Ltd overvalued?
According to Wall Street analysts OncoSil Medical Ltd’s price is currently Overvalued.
Does OncoSil Medical Ltd pay dividends?
OncoSil Medical Ltd does not currently pay dividends.
What is OncoSil Medical Ltd’s EPS estimate?
OncoSil Medical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoSil Medical Ltd have?
OncoSil Medical Ltd has 30,697,231 shares outstanding.
What happened to OncoSil Medical Ltd’s price movement after its last earnings report?
OncoSil Medical Ltd reported an EPS of -AU$0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.538%.
Which hedge fund is a major shareholder of OncoSil Medical Ltd?
Currently, no hedge funds are holding shares in AU:OSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OncoSil Medical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:OSL Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$114.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
―
20 days / 200 days
Momentum
-67.40%
12-Months-Change
Fundamentals
Return on Equity
-372.27%
Trailing 12-Months
Asset Growth
-37.99%
Trailing 12-Months
Company Description
OncoSil Medical Ltd
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia.
Technical Analysis
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―
4DMedical Ltd
―